Description
The VA North Texas Health Care System is conducting market research to identify vendors that can supply a set of FDA‑approved blood‑bank reagents for manual blood typing and antibody detection. Vendors must be able to provide the listed ALBAcyte reagents, demonstrate FDA approval, a quality plan, and sufficient inventory, and submit a capability statement by the deadline.
• Required reagents include ALBAcyte A1, A2, B, IgG Sensitized, Antibody ID Panel, and C3‑Coated Red Blood Cells with annual quantities ranging from 7 to 52 units per item.
• The contract’s base period runs May 1 2027 – April 30 2028 with four optional one‑year extensions, potentially totaling five years.
• All shipments are FOB Destination; vendors must provide appropriate containers and documentation of FDA approval.